RecruitingNCT01247597
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Studying DICER1 tumor-predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Douglas R Stewart, M.D.National Cancer Institute (NCI)
- Enrollment
- 1500 enrolled
- Eligibility
- 99 years · All sexes
- Timeline
- 2011
Study locations (2)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- National Cancer Institute - Shady Grove, Rockville, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01247597 on ClinicalTrials.govOther trials for DICER1 tumor-predisposition syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06647953Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGNANCT01464606International Pleuropulmonary Blastoma (PPB) Treatment and Biology RegistryChildren's Hospitals and Clinics of Minnesota